DJIA 17,390.52 195.10 1.13%
NASDAQ 4,630.74 64.60 1.41%
S&P 500 2,018.05 23.40 1.17%
market minute promo

Cubist Pharmaceuticals (NASDAQ: CBST)

72.29 -0.21 (-0.29%)

REAL-TIME: Last trade at

Extended Hours: $72.30 $0.01 (0.01%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

CBST $72.29 -0.29%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $73.35
Previous Close $72.50
Daily Range $72.08 - $74.05
52-Week Range $58.50 - $82.12
Market Cap $5.5B
P/E Ratio -142.16
Dividend (Yield) $0.00 (0.0%)
Volume 571,573
Average Daily Volume 765,500
Current FY EPS $1.51

Sector

Healthcare

Industry

Drugs

Cubist Pharmaceuticals (CBST) Description

A biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Website: http://www.cubist.com/

News & Commentary Rss Feed

3 States With the Worst Hospital Infection Rates

According to CDC data, these states have the largest percentage of hospitals that are failing to meet their benchmarks; here's what the government is doing about it.

Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen - Analyst Blog

Why We Think Cubist Pharmaceuticals Has Incredible Upside

Cubist Pharmaceuticals' Q3 Earnings Beat Expectations - Analyst Blog

5 Unusual-Volume Stocks Poised for Breakouts

Cubist Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for CBST

Trade-Ideas: Cubist Pharmaceuticals (CBST) Is Today's "Storm The Castle" Stock

Cubist Pharmaceuticals Inc's Momentum Builds As Anti-Infection Product Line Grows

Cubist reported better than expected third quarter results this week.

Cubist Pharmaceuticals' (CBST) CEO Mike Bonney on Q3 2014 Results - Earnings Call Transcript

Bank Of America Q3 Small & Mid-Cap Biotech Preview

See More CBST News...

CBST's Top Competitors

CBST $72.29 (-0.29%)
Current stock: CBST
AMGN $162.18 (0.37%)
Current stock: AMGN
GILD $112.00 (-1.94%)
Current stock: GILD
BIIB $321.08 (0.02%)
Current stock: BIIB